tetano
Editor, Senior Moderator
Dermatol Ther
. 2020 Sep 25.
doi: 10.1111/dth.14332. Online ahead of print.
No SARS-CoV-2 antibody response in 25 patients with pseudo-chilblains
Alexandre Docampo-Sim?n[SUP] 1 [/SUP], Mar?a Jos? S?nchez-Pujol[SUP] 1 [/SUP], Adelina Gimeno-Gascon[SUP] 2 [/SUP], Juan Carlos Palaz?n-Cabanes[SUP] 1 [/SUP], Gloria Juan-Carpena[SUP] 1 [/SUP], Eduardo Vergara-De Caso[SUP] 1 [/SUP], Iris Gonz?lez-Villanueva[SUP] 1 [/SUP], Mar Blanes-Mart?nez[SUP] 1 [/SUP], Isabel Betlloch-Mas[SUP] 1 [/SUP]
Affiliations
Abstract
Chilblain-like acral lesions have been identified in some COVID-19 patients. It has been suggested that these pseudo-chilblains could be a specific marker of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with these lesions have had negative PCRs, but some authors believe serology tests are likely to give positive results. We designed a prospective study including all patients with pseudo-chilblains treated in out department in April and May 2020 then performed SARS-CoV-2 PCR and serology tests on all available patients. We evaluated 59 patients, of whom 17 had undergone PCR before the study period, all with negative results. For the present study, we performed 20 additional PCRs, serology tests in 25 patients, and a parvovirus B19 antibody test in 15 patients. All results were negative. Our findings counter the hypothesis that serology is likely to reveal SARS-CoV-2 infection in patients with pseudo-chilblains. One hypothesis for our negative results is that the time period between symptom onset and antibody production is longer in these patients; another is that the lesions are caused by behavioural changes during lockdown rather than SARS-CoV-2 infection. We nevertheless maintain that COVID-19 should be ruled out in people presenting with chilblain-like lesions. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Chilblains; Coronavirus; SARS-CoV-2; acral.
. 2020 Sep 25.
doi: 10.1111/dth.14332. Online ahead of print.
No SARS-CoV-2 antibody response in 25 patients with pseudo-chilblains
Alexandre Docampo-Sim?n[SUP] 1 [/SUP], Mar?a Jos? S?nchez-Pujol[SUP] 1 [/SUP], Adelina Gimeno-Gascon[SUP] 2 [/SUP], Juan Carlos Palaz?n-Cabanes[SUP] 1 [/SUP], Gloria Juan-Carpena[SUP] 1 [/SUP], Eduardo Vergara-De Caso[SUP] 1 [/SUP], Iris Gonz?lez-Villanueva[SUP] 1 [/SUP], Mar Blanes-Mart?nez[SUP] 1 [/SUP], Isabel Betlloch-Mas[SUP] 1 [/SUP]
Affiliations
- PMID: 32975345
- DOI: 10.1111/dth.14332
Abstract
Chilblain-like acral lesions have been identified in some COVID-19 patients. It has been suggested that these pseudo-chilblains could be a specific marker of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with these lesions have had negative PCRs, but some authors believe serology tests are likely to give positive results. We designed a prospective study including all patients with pseudo-chilblains treated in out department in April and May 2020 then performed SARS-CoV-2 PCR and serology tests on all available patients. We evaluated 59 patients, of whom 17 had undergone PCR before the study period, all with negative results. For the present study, we performed 20 additional PCRs, serology tests in 25 patients, and a parvovirus B19 antibody test in 15 patients. All results were negative. Our findings counter the hypothesis that serology is likely to reveal SARS-CoV-2 infection in patients with pseudo-chilblains. One hypothesis for our negative results is that the time period between symptom onset and antibody production is longer in these patients; another is that the lesions are caused by behavioural changes during lockdown rather than SARS-CoV-2 infection. We nevertheless maintain that COVID-19 should be ruled out in people presenting with chilblain-like lesions. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Chilblains; Coronavirus; SARS-CoV-2; acral.